{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:34:53Z","timestamp":1787582093504,"version":"build-2736575974"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Therapeutic failure in EGFR-mutant non-small cell lung cancer (NSCLC) is commonly viewed as a consequence of acquired resistance, but this perspective may overlook an earlier and potentially more tractable phase marked by the survival of residual cells after effective EGFR inhibition. In this Review, we define the mitochondrial niche as a temporally bounded, hypothesis-generating model of early residual disease in which tumor-cell mitochondrial stress adaptation is considered alongside fibroblast\u2013matrix support and incomplete immune clearance. The conceptual contribution of this framework is to place independently studied tumor-intrinsic, stromal, and immune processes on a common temporal axis and to generate testable questions about their potential interaction; whether these processes coexist and function as a coordinated niche in EGFR-mutant residual disease has not yet been directly demonstrated. We distinguish DTPs and cycling persisters as experimentally defined cell states, MRD as a clinical detection state, and acquired resistance as overt regrowth under continued therapy. In selected preclinical models, EGFR-targeted therapy is associated with survival states involving mitochondrial fuel use, redox control, organelle-quality surveillance, or apoptotic restraint. In parallel, selected cancer-associated fibroblast states may buffer therapy-induced stress, whereas treatment-associated inflammatory remodeling often fails to generate productive antitumor immunity. By treating residual disease as a distinct, low-burden and testable state rather than as direct evidence of a single persister ecology, this framework prioritizes candidate biomarker classes and mechanism-based interventions for prospective validation before stable resistance is established. Candidate readouts include driver-ctDNA kinetics, residual-lesion status, stromal-state markers, and selected immune features, all requiring prospective validation.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1908826","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:51:42Z","timestamp":1787579502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial niches of residual disease in EGFR-mutant NSCLC: immune-constrained persistence and therapeutic interception"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhanhao","family":"Liang","sequence":"first","affiliation":[{"name":"First Affiliated Hospital, Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xutong","family":"Zhao","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital, Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingru","family":"Jiang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital, Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meizhu","family":"Zhou","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital, Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Cheng","sequence":"additional","affiliation":[{"name":"College of Health-Preservation and Wellness, Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.05.027","article-title":"Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stages I to IIIA EGFR-mutant non-small cell lung cancer","volume":"18","author":"Jung","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13624","article-title":"Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells by mTOR activation through Akt-independent pathway","volume":"109","author":"Yamazaki","year":"2018","journal-title":"Cancer Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1038\/s41467-024-48433-8","article-title":"Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202506950","article-title":"EGFR-TKIs induced DPP4 drives metabolic reprogramming of persister cells in lung cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-0433","article-title":"Transfer of damaged mitochondria from cancer cells to cancer-associated fibroblasts promotes tyrosine kinase inhibitor tolerance in EGFR-mutant lung cancer","volume":"86","author":"Liu","year":"2026","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jtho.2020.12.010","article-title":"Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73\/adenosine pathway as a potential therapeutic target","volume":"16","author":"Le","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1515","article-title":"Eradicating drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy","volume":"15","author":"Baldacci","year":"2025","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02475-9","article-title":"Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies","volume":"130","author":"Leonetti","year":"2024","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2811","article-title":"Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer","volume":"81","author":"Kashima","year":"2021","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s42003-024-06190-w","article-title":"Genome-wide CRISPR screens identify the YAP\/TEAD axis as a driver of persister cells in EGFR mutant lung cancer","volume":"7","author":"Pfeifer","year":"2024","journal-title":"Commun Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13388","article-title":"Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma","volume":"7","author":"Martin","year":"2016","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI160152","article-title":"Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse","volume":"132","author":"Nie","year":"2022","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1038\/s41467-025-59623-3","article-title":"Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma","volume":"16","author":"Shinozaki","year":"2025","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","article-title":"Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing","volume":"182","author":"Maynard","year":"2020","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100007","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061574","article-title":"Effect of osimertinib on CTCs and ctDNA in EGFR mutant non-small cell lung cancer patients: the prognostic relevance of liquid biopsy","volume":"14","author":"Kallergi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-371","article-title":"The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment","volume":"10","author":"Ma","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0741","article-title":"Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41698-024-00609-7","article-title":"Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using Malignant pleural effusion","volume":"8","author":"Lee","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41392-025-02481-8","article-title":"A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib","volume":"10","author":"Shi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13307","article-title":"Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGF\u03b22-bioenergetics-mitochondrial priming","volume":"7","author":"Thiagarajan","year":"2016","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.061","article-title":"Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer","volume":"18","author":"Momcilovic","year":"2017","journal-title":"Cell Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.CAN-22-2370","article-title":"PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-023-01222-0","article-title":"C-IGF1R encoded by cIGF1R acts as a molecular switch to restrict mitophagy of drug-tolerant persister tumour cells in non-small cell lung cancer","volume":"30","author":"Wang","year":"2023","journal-title":"Cell Death Differ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.12.029","article-title":"Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis","volume":"641","author":"Konishi","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-303","article-title":"Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.celrep.2019.06.026","article-title":"Branched-chain amino acid metabolic reprogramming orchestrates drug resistance to EGFR tyrosine kinase inhibitors","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101663","article-title":"In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma","volume":"5","author":"Nokin","year":"2024","journal-title":"Cell Rep Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.canlet.2021.03.013","article-title":"Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition","volume":"507","author":"You","year":"2021","journal-title":"Cancer Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-3748","article-title":"MYLK-AS1 enhances glutamine metabolism to promote EGFR inhibitor resistance in non-small cell lung cancer","volume":"85","author":"Qu","year":"2025","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s44320-025-00141-1","article-title":"Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures","volume":"21","author":"Hsu","year":"2025","journal-title":"Mol Syst Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbadis.2017.12.021","article-title":"Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF\/IGF-1\/ANXA2 signaling","volume":"1864","author":"Yi","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12838","article-title":"Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancer-associated fibroblasts with EGFR-TKI resistance-promoting phenotype: a study of 18 cases of cancer-associated fibroblasts","volume":"69","author":"Suzuki","year":"2019","journal-title":"Pathol Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7150\/jca.111383","article-title":"Cancer-associated fibroblasts confer osimertinib resistance in non-small cell lung cancer cells via NRG1-mediated HER3\/AKT signaling","volume":"16","author":"Zheng","year":"2025","journal-title":"J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/srep46662","article-title":"CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR tyrosine kinase inhibitors","volume":"7","author":"Ishibashi","year":"2017","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","article-title":"Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms","volume":"39","author":"Hu","year":"2021","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03318-y","article-title":"Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1\/glycolysis\/H3K18la positive feedback loop","volume":"44","author":"Zhang","year":"2025","journal-title":"Oncogene"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03461-6","article-title":"Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma","volume":"44","author":"Shi","year":"2025","journal-title":"Oncogene"},{"key":"B54","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1186\/s12885-022-09877-7","article-title":"Cancer-associated fibroblasts strengthen cell proliferation and EGFR TKIs resistance through aryl hydrocarbon receptor dependent signals in non-small cell lung cancer","volume":"22","author":"Feng","year":"2022","journal-title":"BMC Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/cas.13860","article-title":"Mutational activation of the epidermal growth factor receptor down\u2010regulates major histocompatibility complex class I expression via the extracellular signal\u2010regulated kinase in non\u2013small cell lung cancer","volume":"110","author":"Watanabe","year":"2019","journal-title":"Cancer Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s40425-019-0643-8","article-title":"Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors","volume":"7","author":"Ayeni","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00181-4","article-title":"A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer","volume":"5","author":"Gurule","year":"2021","journal-title":"NPJ Precis Onc"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107815","article-title":"EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment","volume":"192","author":"Chen","year":"2024","journal-title":"Lung Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15701","article-title":"EGFR inhibition in EGFR\u2010mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment","volume":"114","author":"Shiiya","year":"2022","journal-title":"Cancer Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010124","article-title":"EGFR-tyrosine kinase inhibitors induced activation of the autocrine CXCL10\/CXCR3 pathway through crosstalk between the tumor and the microenvironment in EGFR-mutant lung cancer","volume":"15","author":"Hong","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1077203","article-title":"Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer","volume":"14","author":"Lin","year":"2023","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx183","article-title":"Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment","volume":"28","author":"Haratani","year":"2017","journal-title":"Ann Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","article-title":"CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance","volume":"41","author":"Nilsson","year":"2023","journal-title":"Cancer Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41392-025-02482-7","article-title":"MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer","volume":"10","author":"Takamori","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102199","article-title":"EGFR TKIs suppress MUC1 glycosylation through the PI3K\/AKT\/SP1\/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2022.12.003","article-title":"Single-cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung adenocarcinoma xenograft model","volume":"18","author":"Moghal","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41698-022-00337-w","article-title":"The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells","volume":"6","author":"Criscione","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0846","article-title":"Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation","volume":"21","author":"Yoshida","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100779","article-title":"Solid predominant histology and high podoplanin expression in cancer-associated fibroblast predict primary resistance to osimertinib in EGFR-mutated lung adenocarcinoma","volume":"6","author":"Uehara","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.016","article-title":"Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation","volume":"13","author":"Su","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01455","article-title":"Soluble PD-L1 as a predictor of the response to EGFR-TKIs in non-small cell lung cancer patients with EGFR mutations","volume":"10","author":"Jia","year":"2020","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03330-1","article-title":"Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40364-023-00470-z","article-title":"Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer","volume":"11","author":"Liu","year":"2023","journal-title":"biomark Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41419-024-06940-y","article-title":"Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer","volume":"15","author":"Izumi","year":"2024","journal-title":"Cell Death Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106584","article-title":"Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes","volume":"26","author":"Xie","year":"2023","journal-title":"iScience"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","article-title":"Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2321","article-title":"ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer","volume":"26","author":"Okura","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15674","article-title":"Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer","volume":"114","author":"Takahashi","year":"2023","journal-title":"Cancer Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI198418","article-title":"Osimertinib activates a TGF-\u03b22-dependent secretory program that drives lung adenocarcinoma progression","volume":"136","author":"Ghosh","year":"2026","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1531353","article-title":"Osimertinib improves the immune microenvironment of lung cancer by downregulating PD-L1 expression of vascular endothelial cells and enhances the antitumor effect of bevacizumab","volume":"2022","author":"Xiao","year":"2022","journal-title":"J Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70068","article-title":"CD24 is a promising immunotherapeutic target for enhancing efficacy of third-generation EGFR-TKIs on EGFR-mutated lung cancer","volume":"45","author":"Liang","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1693","article-title":"The activity of EGFR CAR NK and CAR T cells against EGFR inhibitor-resistant NSCLC and drug-tolerant persister cells","volume":"31","author":"Yang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2026.05.020","article-title":"Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer","volume":"44","author":"Liao","year":"2026","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0751","article-title":"CD8+ T-cell responses are boosted by dual PD-1\/VEGFR2 blockade after EGFR inhibition in egfr-mutant lung cancer","volume":"10","author":"Nishii","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100706","article-title":"Immune cell dynamics in EGFR-mutated NSCLC treated with afatinib and pembrolizumab: results from a phase IB study","volume":"5","author":"Riess","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103435","article-title":"Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"87","author":"Sampath","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0438","article-title":"ASCL1 drives tolerance to osimertinib in EGFR mutant lung cancer in permissive cellular contexts","volume":"84","author":"Hu","year":"2024","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.10.001","article-title":"GSTA1 conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-mutant lung adenocarcinoma","volume":"21","author":"Zhang","year":"2026","journal-title":"J Thorac Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0304","article-title":"Increased synthesis of MCL-1 protein underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors and provides a novel drug target","volume":"24","author":"Song","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217962","article-title":"Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib","volume":"632","author":"Ma","year":"2025","journal-title":"Cancer Lett"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111736","article-title":"Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer","volume":"28","author":"Kim","year":"2025","journal-title":"iScience"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01143-9","article-title":"Spatially resolved whole-transcriptomic profiling of EGFR-mutated lung adenocarcinomas stratified by PD-L1 expression","volume":"49","author":"Yu","year":"2026","journal-title":"Cell Oncol (Dordr)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01577-z","article-title":"PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways","volume":"57","author":"Shin","year":"2025","journal-title":"Exp Mol Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1004","article-title":"TAK1 promotes an immunosuppressive tumor microenvironment through cancer-associated fibroblast phenotypic conversion in pancreatic ductal adenocarcinoma","volume":"30","author":"Sheng","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27606","article-title":"TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades","volume":"11","author":"Scarneo","year":"2020","journal-title":"Oncotarget"},{"key":"B100","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41419-025-08013-0","article-title":"Targeting tumor intrinsic TAK1 engages TNF-\u03b1-driven cell death through distinct mechanisms and enhances cancer immunotherapy","volume":"16","author":"Huska","year":"2025","journal-title":"Cell Death Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.04.039","article-title":"Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment","volume":"145","author":"Beagan","year":"2020","journal-title":"Lung Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15608","article-title":"High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib","volume":"114","author":"Yoshimura","year":"2023","journal-title":"Cancer Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1908826\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:51:43Z","timestamp":1787579503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1908826\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":102,"alternative-id":["10.3389\/fimmu.2026.1908826"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1908826","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1908826"}}